Copyright
©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1663-1676
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1663
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1663
Ref. | Study design | Number of patients | Drugs | HCC | Portal hypertension-related complications |
Kozbial et al[32], 2018 | Prospective | 551 | DAA | 16 (4.1%) | Ascites: 3.1%; variceal hemorrhage: 1%; hepatic encephalopathy: 0% |
Masuzaki et al[36], 2009 | Prospective | 984 | DAA | 77 (2.9% per 1 person-year); HCC risk: 45.5 times higher in LS > 25 kPa | NA |
Afdhal et al[39], 2017 | Prospective | 50 | DAA | LS improvement in patients who did not develop HCC during follow-up (42.6% reduction in patients without HCC vs 13.6% in HCC group) | 24% patients had ≥ 20% decreases in HVPG during treatment (89% subjects with baseline HVPG ≥ 12 mmHg had a ≥ 20% reduction in HVPG after SVR) |
Giannini et al[51], 2019 | Prospective | 52 | DAA | 4 (7.7%) | Clinical decompensation: 0% |
Tachi et al[58], 2017 | Prospective | 263 | DAA | 19 (7.2%) | NA |
Foster et al[60], 2016 | Retrospective, observational | 467 | DAA | NA | MELD improvement (0.85, SD 2.54); composite adverse outcome in 52.0% (treated) vs 61.7% (untreated) |
Rinaldi et al[63], 2019 | Multicenter, prospective | 258 | DAA | 35 (13.6%) | NA |
Ravaioli et al[68], 2018 | Retrospective | 139 | DAA | 20 (14.4%) | NA |
Pan et al[70], 2018 | Retrospective | 84 | DAA | 4 (4.8%) | NA |
Toyoda et al[75], 2015 | Retrospective/prospective | 522 | IFN-based | 18 (1.2% after five yr; 4.3% after ten yr) | NA |
D’Ambrosio et al[77], 2018 | Prospective | 38 | DAA | 5 (13%) | Clinical decompensation: 0% |
Lleo et al[78], 2019 | Prospective | 1927 | DAA | Previous HCC: 38/161 (recurrence rate: 24.8 per 100-yr); No previous HCC: 50/1766 (incidence rate: 2.4 per 100-yr) | NA |
Hamada et al[79], 2018 | Retrospective | 196 | DAA | 8 (4.1%) | NA |
- Citation: Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676
- URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1663.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1663